Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin

Journal of Pharmaceutical Sciences

Volumn 103, Issue 5, 2014, Pages 1367-1374

  Torosantucci, Riccardo ^a   Brinks, Vera ^b   Kijanka, Grzegorz ^b   Halim, Liem Andhyk ^b   Sauerborn, Melody ^b   Schellekens, Huub ^b   Jiskoot, Wim ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

immune response; nanoparticles; oxidation; physicochemical properties; protein aggregation; protein formulation

Indexed keywords

INSULIN ANTIBODY; INSULIN DETEMIR; ISOPHANE INSULIN; NANOPARTICLE; NEUTRAL INSULIN; POLYSTYRENE; RECOMBINANT HUMAN INSULIN; INSULIN; POLYSTYRENE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG CONJUGATION; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; MOUSE MODEL; NONHUMAN; OXIDATION; PHYSICAL CHEMISTRY; PROTEIN AGGREGATION; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HUMAN; IMMUNOLOGY; MEDICINAL CHEMISTRY; PARTICLE SIZE; PROCEDURES;

ANIMALS; ANTIBODY FORMATION; CHEMISTRY, PHARMACEUTICAL; HUMANS; IMMUNE TOLERANCE; INSULIN; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NANOPARTICLES; PARTICLE SIZE; POLYSTYRENES; RECOMBINANT PROTEINS;

EID: 84897979786     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23935     Document Type: Article

References (35)

1. Gerngross TU,. 2004. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22: 1409-1414.
2. Johnson IS,. 1983. Human insulin from recombinant DNA technology. Science 219: 632-637.
3. Schellekens H,. 2008. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14: 191-202.
4. Schellekens H,. 2008. The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative. Clin Ther 30 Suppl B: S50-S51.
5. Sauerborn M, Brinks V, Jiskoot W, Schellekens H,. 2010. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 31: 53-59.
6. Schellekens H,. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20 Suppl 6: vi3-vi9.
7. Torosantucci R, Schöneich C, Jiskoot W,. 2014. Oxidation of therapeutic proteins and peptides: Structural and biological consequences. Pharm Res 31: 541-553.
8. Torosantucci R, Sharov VS, van Beers M, Brinks V, Schöneich C, Jiskoot W,. 2013. Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: Potential implications for protein aggregation and immunogenicity. Mol Pharm 10: 2311-2322.
9. Kumar S, Singh SK, Wang XL, Rup B, Gill D,. 2011. Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm Res 28: 949-961.
10. Rosenberg AS,. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8: E501-E507.
11. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W,. 2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22: 1997-2006.
12. Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H,. 2005. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res 22: 847-851.
13. van Beers MM, Sauerborn M, Gilli F, Hermeling S, Brinks V, Schellekens H, Jiskoot W,. 2011. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta. J Immunol Methods 352: 32-37.
14. Ottesen JL, Nilsson P, Jami J, Weilguny D, Duhrkop M, Bucchini D, Havelund S, Fogh JM,. 1994. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37: 1178-1185.
15. Brange J, Langkjaer L, Havelund S, Volund A,. 1992. Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm Res 9: 715-726.
16. Kalkanidis M, Pietersz GA, Xiang SD, Mottram PL, Crimeen-Irwin B, Ardipradja K, Plebanski M,. 2006. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods 40: 20-29.
17. Torosantucci R, Mozziconacci O, Sharov V, Schöneich C, Jiskoot W,. 2012. Chemical modifications in aggregates of recombinant human insulin induced by metal-catalyzed oxidation: Covalent cross-linking via Michael addition to tyrosine oxidation products. Pharm Res 29: 2276-2293.
18. Torosantucci R, Kukrer B, Mero A, Van Winsen M, Tantipolphan R, Jiskoot W,. 2011. Plain and mono-pegylated recombinant human insulin exhibit similar stress-induced aggregation profiles. J Pharm Sci 100: 2574-2585.
19. European Directorate for the Quality of Medicines (EDQM). 2001. Insulin, human.
20. The United States Pharmacopeia Convention, Inc. 2002. Insulin.
21. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA,. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289: 1-16.
22. Bobst CE, Abzalimov RR, Houde D, Kloczewiak M, Mhatre R, Berkowitz SA, Kaltashov IA,. 2008. Detection and characterization of altered conformations of protein pharmaceuticals using complementary mass spectrometry-based approaches. Anal Chem 80: 7473-7481.
23. Xie L, Tsou CL,. 1993. Comparison of secondary structures of insulin and proinsulin by FTIR. J Protein Chem 12: 483-487.
24. Mulinacci F, Poirier E, Capelle MA, Gurny R, Arvinte T,. 2011. Enhanced physical stability of human calcitonin after methionine oxidation. Eur J Pharm Biopharm 78: 229-238.
25. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W,. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95: 1084-1096.
26. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S,. 2012. Immunogenicity of protein aggregates-Concerns and realities. Int J Pharm 431: 1-11.
27. van Beers MM, Bardor M,. 2012. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 7: 1473-1484.
28. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA,. 2010. Nanoparticles and the immune system. Endocrinology 151: 458-465.
29. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W,. 2011. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 28: 2393-2402.
30. Thomas JW, Virta VJ, Nell LJ,. 1985. Heterogeneity and specificity of human anti-insulin antibodies determined by isoelectric focusing. J Immunol 134: 1048-1052.
31. Allauzen S, Joly S, Granier C, Molina F, Bouix O, Pau B, Bouanani M,. 1995. Immunoanalysis of human insulin using monoclonal-antibodies reveals antigenicity of evolutionarily conserved residues. Mol Immunol 32: 27-36.
32. Keck K,. 1975. Ir-gene control of immunogenicity of insulin and A-chain loop as a carrier determinant. Nature 254: 78-79.
33. Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H,. 2012. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. MAbs 4: 740-752.
34. Mianowska B, Szadkowska A, Pietrzak I, Zmyslowska A, Wegner O, Tomczonek J, Bodalski J, Mlynarski W,. 2011. Immunogenicity of different brands of human insulin and rapid-acting insulin analogs in insulin-naive children with type 1 diabetes. Pediatr Diabetes 12: 78-84.
35. Kijanka G, Jiskoot W, Schellekens H, Brinks V,. 2013. Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice. Pharm Res 30: 1553-1560.